对制药工艺模型和模型风险框架的研究

IF 5.2 2区 医学 Q1 PHARMACOLOGY & PHARMACY
Thomas F. O'Connor , Sharmista Chatterjee , Johnny Lam , Dolores Hernán Pérez de la Ossa , Leticia Martinez-Peyrat , Marcel H.N. Hoefnagel , Adam C. Fisher
{"title":"对制药工艺模型和模型风险框架的研究","authors":"Thomas F. O'Connor ,&nbsp;Sharmista Chatterjee ,&nbsp;Johnny Lam ,&nbsp;Dolores Hernán Pérez de la Ossa ,&nbsp;Leticia Martinez-Peyrat ,&nbsp;Marcel H.N. Hoefnagel ,&nbsp;Adam C. Fisher","doi":"10.1016/j.ijpx.2024.100274","DOIUrl":null,"url":null,"abstract":"<div><p>Process models are a growing tool for pharmaceutical manufacturing process design and control. The Industry 4.0 paradigm promises to increase the amount of data available to understand manufacturing processes. Tools such as Artificial Intelligence (AI) might accelerate process development and allow better predictions of process trajectories. Several examples of process improvements realized through the application of process models have been shown in lyophilization, chromatography, fluid bed drying, bioreactor control, continuous direct compression, and wet granulation. An important consideration of implementing a process model is determining the impact of the model on the quality of the product and the risks associated with model maintenance over the product lifecycle. Several regulatory documents address risk-based considerations for process models. This work discusses existing risk-based frameworks for model validation and lifecycle maintenance that could aid the adoption of process models in pharmaceutical manufacturing. Hypothetical case studies illustrate the implications of applying a model risk framework to facilitate model validation and lifecycle maintenance in the manufacture of pharmaceuticals and biological products.</p></div>","PeriodicalId":14280,"journal":{"name":"International Journal of Pharmaceutics: X","volume":null,"pages":null},"PeriodicalIF":5.2000,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S259015672400046X/pdfft?md5=9ffcd3019bddcac26895281a73457971&pid=1-s2.0-S259015672400046X-main.pdf","citationCount":"0","resultStr":"{\"title\":\"An examination of process models and model risk frameworks for pharmaceutical manufacturing\",\"authors\":\"Thomas F. O'Connor ,&nbsp;Sharmista Chatterjee ,&nbsp;Johnny Lam ,&nbsp;Dolores Hernán Pérez de la Ossa ,&nbsp;Leticia Martinez-Peyrat ,&nbsp;Marcel H.N. Hoefnagel ,&nbsp;Adam C. Fisher\",\"doi\":\"10.1016/j.ijpx.2024.100274\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Process models are a growing tool for pharmaceutical manufacturing process design and control. The Industry 4.0 paradigm promises to increase the amount of data available to understand manufacturing processes. Tools such as Artificial Intelligence (AI) might accelerate process development and allow better predictions of process trajectories. Several examples of process improvements realized through the application of process models have been shown in lyophilization, chromatography, fluid bed drying, bioreactor control, continuous direct compression, and wet granulation. An important consideration of implementing a process model is determining the impact of the model on the quality of the product and the risks associated with model maintenance over the product lifecycle. Several regulatory documents address risk-based considerations for process models. This work discusses existing risk-based frameworks for model validation and lifecycle maintenance that could aid the adoption of process models in pharmaceutical manufacturing. Hypothetical case studies illustrate the implications of applying a model risk framework to facilitate model validation and lifecycle maintenance in the manufacture of pharmaceuticals and biological products.</p></div>\",\"PeriodicalId\":14280,\"journal\":{\"name\":\"International Journal of Pharmaceutics: X\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":5.2000,\"publicationDate\":\"2024-08-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S259015672400046X/pdfft?md5=9ffcd3019bddcac26895281a73457971&pid=1-s2.0-S259015672400046X-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Pharmaceutics: X\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S259015672400046X\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Pharmaceutics: X","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S259015672400046X","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

工艺模型是制药生产工艺设计和控制的一个日益重要的工具。工业 4.0 范式有望增加可用于了解生产流程的数据量。人工智能(AI)等工具可能会加速工艺开发并更好地预测工艺轨迹。在冻干、色谱、流化床干燥、生物反应器控制、连续直接压缩和湿法制粒等领域,都有应用工艺模型实现工艺改进的实例。实施工艺模型的一个重要考虑因素是确定模型对产品质量的影响以及在产品生命周期内与模型维护相关的风险。一些监管文件涉及工艺模型的基于风险的考虑因素。这项工作讨论了现有的基于风险的模型验证和生命周期维护框架,这些框架可以帮助在药品生产中采用工艺模型。假设案例研究说明了在药品和生物制品生产中应用模型风险框架促进模型验证和生命周期维护的意义。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
An examination of process models and model risk frameworks for pharmaceutical manufacturing

Process models are a growing tool for pharmaceutical manufacturing process design and control. The Industry 4.0 paradigm promises to increase the amount of data available to understand manufacturing processes. Tools such as Artificial Intelligence (AI) might accelerate process development and allow better predictions of process trajectories. Several examples of process improvements realized through the application of process models have been shown in lyophilization, chromatography, fluid bed drying, bioreactor control, continuous direct compression, and wet granulation. An important consideration of implementing a process model is determining the impact of the model on the quality of the product and the risks associated with model maintenance over the product lifecycle. Several regulatory documents address risk-based considerations for process models. This work discusses existing risk-based frameworks for model validation and lifecycle maintenance that could aid the adoption of process models in pharmaceutical manufacturing. Hypothetical case studies illustrate the implications of applying a model risk framework to facilitate model validation and lifecycle maintenance in the manufacture of pharmaceuticals and biological products.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
International Journal of Pharmaceutics: X
International Journal of Pharmaceutics: X Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science
CiteScore
6.60
自引率
0.00%
发文量
32
审稿时长
24 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信